| Academic Year 2007-2008 |
| Oct 3 |
Scott Diegel |
| Nov 7 |
Ellen Roecker - Clinical Trialists' Journey to the Last Frontier |
| Dec 5 |
Michelle Detry |
| Feb 11, Mon. |
Robin Bechhofer - Patient-Reported Outcome Measures: Selected Regulatory Issues |
| Mar 5 |
Jan Feyzi |
| Apr 2 |
Marian Fisher |
| May 7 |
Melissa Schultz |
| Academic Year 2006-2007 |
| December 13 |
Anti CD3 Monoclonal Antibody in New-onset Type I Diabetes |
| February 7 |
A 1-year Extension to the Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial |
| April 18 |
CB1 Inhibition in the Treatment of Obesity |
| Academic Year 2005-2006 |
May 10 |
The Rationale and Design of the Trial to Reduce Cardiovascular
Events with Aranesp Therapy (TREAT Trial) |
| March 1 |
The Search for an Association between Statins and Cancer Risk |
| February 1 |
Combining Information across Studies: Methods, Pitfalls, and Limitations |
| December 7 |
FDA Advisory Meeting (Arthritis Committee, Drug Safety and Cancer Risk Management Committee): February 16-18, 2005 |
| November 2 |
The Studies of Oral Enozimone Therapy in Advanced Heart Failure (ESSENTIAL):
Design and Final Results |
| October 5 |
Advanced Issues in the Design and Conduct of Randomised Clinical Trials-
A Discussion of the Oxford International Symposium |
| Academic Year 2004-2005 |
| May 18 |
Tolvaptan in Patients with Congestive Heart Failure:
Background and Design of the Everest Trial |
| April 6< |
The TNT (Titrating to New Targets) Study: ACC Presentation
and Review of the Monitoring Process |
| March 16 |
Basic Issues in Gene Therapy |
| December 1 |
Liability in the Data Monitoring Process |
| November 3 |
Clinical Trials in Pulmonary Arterial Hypertension |
| October 6 |
The Comparison of Medical therapy, Pacing, ANd defibrillatION in
heart failure (COMPANION) Trial: Final Results and FDA Review |
| Academic Year 2002-2003 |
| May 9 |
Title: Celecoxib, a COX-2 Inhibitor, in Cancer Prevention |
| April 9 |
Title: The Carvedilol Post-Infarct Survival Control in LV Dysfunction (CAPRICORN) Trial |
| March 5 |
'The Age-Related Eye Disease Study (AREDS)' |
| February 5 |
Results of the ALLHAT Trial' |
| December 4, 2002 |
'Discussion of Results from the Women's Health Initiative Estrogen Plus Progestin Trial' |
| November 6, 2002 |
'Cholesterol Lowering with Statins: Effect on Cardiovascular Disease' |
| October 2 |
'Precursor Studies of ADOPT (A Diabetes Outcome Progression Trial)' |
| Academic Year 2001-2002 |
| May 1 |
Results of the Endothelin Antagonism with Bosentan and Lowering of Events (ENABLE) Trial |
| April 3 |
The WIZARD Trial |
| March 6 |
The Val-HEFT Trial: Angiotensin-Receptor Blockade in Congestive Heart Failure |
| February 6 |
Managing and Monitoring Multicenter Clinical Trials: Who is in charge of what? |
| January 9 |
FDA Draft Guidance for Clinical Trial Sponsors On the Establishment and Operation of Clinical Trial Data Monitoring Committees |
| December 5 |
Pacemakers, Defibrillators and the Companion Trial |
| November 7 |
Paradoxes in Equivalence Trials |
| October 10 |
Stroke Prevention in Patients with Atrial Fibrillation |
| Academic Year 2000-2001 |
| May 2 |
The PRAISE I and PRAISE II Trials |
| April 4 |
"Uninformed Consent: What Patients at the 'Hutch' Weren't Told About Experiments in Which They Died" |
| February 14 |
The Sharing of Information Between Data Safety Monitoring Boards. |
| January 10 |
A Brief Overview of 30 Years of Experience with Cholesterol-Lowering Trials. Part III. |
| November 1 |
A Brief Overview of 30 Years of Experience with Cholesterol-Lowering Trials. Part II. |
| October 11 |
A Brief Overview of 30 Years of Experience with Cholesterol-Lowering Trials. Part I. |
| September 6 |
A Carvedilol Update: Mortality Results of the COPERNICUS Trial |
